UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

OnKure Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

> 68277Q105 (CUSIP Number)

October 4, 2024 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 \Box Rule 13d-1(b)

 \boxtimes Rule 13d-1(c)

 \Box Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 68277Q105

1	NAMES OF	FRE	PORTING PERSONS					
	D							
	Perceptive A							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) (c)							
	(a) 🗆 (0) 1						
3	SEC USE ONLY							
4	CITIZENSHIP OR PLACE OF ORGANIZATION							
	Delaware							
		5	SOLE VOTING POWER					
			0					
	JMBER OF	6	SHARED VOTING POWER					
	SHARES VEFICIALLY	v						
	WNED BY		1,004,439					
	EACH	7	SOLE DISPOSITIVE POWER					
	EPORTING							
	PERSON WITH:	-						
	vv 1111.	8	SHARED DISPOSITIVE POWER					
			1,004,439					
9	AGGREGA	TE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	1,004,439							
10	CHECK BC	DX I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
	_							
		OF						
11	PERCENT	OF (CLASS REPRESENTED BY AMOUNT IN ROW 9					
	7.9%							
12								
	IA							

CUSIP No. 68277Q105

1	NAMES OI	FRE	PORTING PERSONS					
	Joseph Edelman							
2		PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)						
	(a) 🗆 ((b) [
3	SEC USE ONLY							
5	SEC USE ONLI							
4	CITIZENSHIP OR PLACE OF ORGANIZATION							
	CITIZEND							
	United States of America							
		5	SOLE VOTING POWER					
N	UMBER OF		0					
	SHARES	6	SHARED VOTING POWER					
	NEFICIALLY		1 004 420					
0	WNED BY EACH	7	1,004,439 SOLE DISPOSITIVE POWER					
R	EPORTING	1	SOLE DISFOSITIVE FOWER					
	PERSON		0					
	WITH:		SHARED DISPOSITIVE POWER					
			1,004,439					
9	AGGREGA	TE /	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	1							
10	1,004,439	X T	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
10	CHECK BU	JA I	F THE AUGKEDATE AMOUNT IN KOW (9) EXCLUDES CERTAIN SHAKES (SEE INSTRUCTIONS)					
11		OF (CLASS REPRESENTED BY AMOUNT IN ROW 9					
	7.9%							
12	12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)							
	IN							

CUSIP No. 68277Q105

1	NAMES OF REPORTING PERSONS							
	Perceptive Life Sciences Master Fund, Ltd.							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)							
	(a) 🗆 ((b) [
3								
3	SEC USE ONLY							
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION							
	Cayman Islands							
	Cuymun 15	5	SOLE VOTING POWER					
	UMBER OF	(
	SHARES NEFICIALLY	6	SHARED VOTING POWER					
	WNED BY		1,004,439					
	EACH	7	SOLE DISPOSITIVE POWER					
	EPORTING							
	PERSON WITH:	8	0 SHADED DISDOSITIVE DOWED					
	W1111.	8	SHARED DISPOSITIVE POWER					
			1,004,439					
9	AGGREGA	TE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	1 004 420							
10	1,004,439		F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
10	children be							
11	PERCENT	OF (CLASS REPRESENTED BY AMOUNT IN ROW 9					
	7.9%							
12								
	CO							

Item 1(a). <u>Name of Issuer</u>:

OnKure Therapeutics, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

6707 Winchester Circle, Suite 400 Boulder, CO 80301

Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the "Reporting Persons") are:

Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor New York, NY 10003

Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation

Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, par value \$0.0001 per share ("Common Stock")

Item 2(e). <u>CUSIP Number</u>:

68277Q105

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.

Item 4. <u>Ownership</u>.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 12,652,811 shares of Common Stock outstanding as reported by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on October 8, 2024.

Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Stock. The Master Fund directly holds 1,004,439 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.

Item 5. <u>Ownership of Five Percent or Less of a Class</u>.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. <u>Ownership of More than Five Percent on Behalf of Another Person</u>.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

 Item 8.
 Identification and Classification of Members of the Group.

 Not applicable.
 Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: October 10, 2024

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: October 10, 2024

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member